CTLA4 and non-small cell lung carcinoma: One study showed that the expression of CD3/CTLA-4 was significantly higher in NSCLC patients, which was positively correlated with miR-146a in patients with the CC genotype; thus, miR-146a could predict the treatment effect of ICIs in patients with advanced NSCLC [148].